<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730481</url>
  </required_header>
  <id_info>
    <org_study_id>KX-ORAX-004</org_study_id>
    <nct_id>NCT02730481</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies</brief_title>
  <official_title>A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinex Pharmaceuticals Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athenex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, safety study. Eligible subjects will be adults with
      advanced malignancies. The study includes a pretreatment and treatment phase. The
      pretreatment phase consists of screening and baseline periods. The treatment phase consists
      of 4-week treatment periods and a follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of Oraxol</measure>
    <time_frame>20 weeks</time_frame>
    <description>The highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor response</measure>
    <time_frame>At baseline and every 8 weeks through study completion, approximately 24 months</time_frame>
    <description>RECIST v1.1 criteria defined as complete response, partial response, stable disease or progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of Oraxol in the blood stream</measure>
    <time_frame>3 weeks</time_frame>
    <description>The measurement of Oraxol levels in the blood stream over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The recommended Phase 2 dose of paclitaxel as Oraxol</measure>
    <time_frame>24 months</time_frame>
    <description>The totality of information from the number of participants that reach the MTD (outcome #1), the number of participants that experience abnormal laboratory values and/or adverse events that are related to treatment (outcome #3), and the amount of Oraxol in the blood stream in participants (outcome #4)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ORAXOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules
Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraxol</intervention_name>
    <description>Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.</description>
    <arm_group_label>ORAXOL</arm_group_label>
    <other_name>Paclitaxel and HM30181AK-US</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. ≥18 years of age

          3. Histologically or cytologically confirmed solid tumor that is metastatic or
             unresectable and for which standard curative or palliative measures do not exist or
             are no longer effective

          4. Measurable disease as per RECIST v1.1 criteria

          5. Adequate hematologic status as demonstrated by not requiring transfusion support or
             granulocyte-colony stimulating factor (G-CSF) to maintain: ANC ≥1500 cells/mm3,
             Platelet count ≥100 x 109/L, Hemoglobin ≥10 g/dL

          6. Adequate liver function as demonstrated by:Total bilirubin of ≤1.5 mg/dL or ≤2.0 mg/dL
             for subjects with liver metastasis, Alanine aminotransferase ≤3 x upper limit of
             normal (ULN) or ≤5 x ULN if liver metastasis is present, Alkaline phosphatase ≤3 x ULN
             or ≤5 x ULN if bone or liver metastasis is present

          7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine
             clearance calculation ≥60 mL/min as calculated by the Cockcroft and Gault formula

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          9. Life expectancy of at least 3 months

         10. Women must be postmenopausal (&gt;12 months without menses) or surgically sterile (ie, by
             hysterectomy and/or bilateral oophorectomy) or must be using effective contraception
             (ie, oral contraceptives, intrauterine device, double barrier method of condom and
             spermicide) and agree to continue use of contraception for 30 days after their last
             dose of study drug.

         11. Sexually active male subjects must use a barrier method of contraception during the
             study and agree to continue the use of male contraception for at least 30 days after
             the last dose of study drug.

        Exclusion Criteria:

          1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or
             previous investigational products (IPs)

          2. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever
             is longer

          3. Are currently receiving other medications or radiation intended for the treatment of
             their malignancy

          4. Women of childbearing potential who are pregnant or breastfeeding

          5. Currently taking a concomitant medication

          6. Require therapeutic use of anticoagulation medications

          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, myocardial infarction within the last
             6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease
             requiring oxygen, known bleeding disorders, or any concomitant illness or social
             situation that would limit compliance with study requirements

          8. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI
             disease or other medical condition that, in the opinion of the investigator may
             interfere with oral drug absorption

          9. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type
             reaction to Cremophor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E D Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kinex Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Goldfinch, MBA, CRM</last_name>
    <phone>716-427-2837</phone>
    <email>jgoldfinch@kinexpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanh T Do</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Boland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp;Research Center @ UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sarantopoulos, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

